Payment overview · 2025
General Payments
$124.72
4 reported records · 3 companies
Healthcare provider profile · identity verified
Gretchen Ortiz Sanchez, MD
Allopathic & Osteopathic Physicians|Internal Medicine · YAUCO, PR · NPI 1114948742
Verified facts
What the public records show
CMS Open Payments records show Gretchen Ortiz Sanchez, MD received $124.72 in general payments during 2025 across 4 reported records.
GlaxoSmithKline, LLC. accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 41.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.16 | 34.6% | 1 | 2025 |
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $30.26 | 24.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $124.72 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $30.26 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PBG PUERTO RICO LLC | $30.26 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 723 | 156 |
| Synthroid | Levothyroxine Sodium | 694 | 136 |
| Gabapentin | Gabapentin | 593 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 552 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 331 | 76 |
| Losartan Potassium | Losartan Potassium | 303 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 71 |
| Simvastatin | Simvastatin | 278 | 80 |
| Alendronate Sodium | Alendronate Sodium | 216 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 202 | 52 |
| Omeprazole | Omeprazole | 200 | 47 |
| Metformin Hcl | Metformin Hcl | 196 | 50 |
| Lisinopril | Lisinopril | 191 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 49 |
| Furosemide | Furosemide | 169 | 41 |
| Montelukast Sodium | Montelukast Sodium | 148 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 26 |
| Azithromycin | Azithromycin | 133 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 33 |
| Clonazepam | Clonazepam | 124 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 33 |
| Temazepam | Temazepam | 114 | 18 |
| Glimepiride | Glimepiride | 112 | 31 |
| Jentadueto | Linagliptin/Metformin Hcl | 104 | 16 |
| Irbesartan | Irbesartan | 100 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 30 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 92 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 29 |
| Trazodone Hcl | Trazodone Hcl | 87 | 21 |
| Carvedilol | Carvedilol | 84 | 21 |
| Meclizine Hcl | Meclizine Hcl | 74 | 21 |
| Jardiance | Empagliflozin | 70 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 19 |
| Ezetimibe | Ezetimibe | 66 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 18 |
| Glipizide | Glipizide | 63 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 14 |
| Allopurinol | Allopurinol | 61 | 15 |
| Memantine Hcl | Memantine Hcl | 60 | 13 |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 59 | suppressed |
| Baclofen | Baclofen | 58 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 12 |
| Meloxicam | Meloxicam | 53 | 15 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 52 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 14 |
| Risperidone | Risperidone | 52 | suppressed |
| Cilostazol | Cilostazol | 51 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 49 | suppressed |
| Tradjenta | Linagliptin | 49 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 13 |
| Atenolol | Atenolol | 47 | 12 |
| Levofloxacin | Levofloxacin | 46 | 39 |
| Sulindac | Sulindac | 45 | suppressed |
| Humalog | Insulin Lispro | 44 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 22 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Mupirocin | Mupirocin | 39 | 30 |
| Nabumetone | Nabumetone | 39 | 18 |
| Nitroglycerin | Nitroglycerin | 39 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 22 |
| Finasteride | Finasteride | 37 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 27 |
| Fluconazole | Fluconazole | 35 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | 11 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 13 |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 11 |
| Prednisone | Prednisone | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | 11 |
| Travoprost | Travoprost | 24 | suppressed |
| Tobramycin | Tobramycin | 23 | 20 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Methylprednisolone | Methylprednisolone | 20 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 18 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 19 | 17 |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 12 |
| Lorazepam | Lorazepam | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Anastrozole | Anastrozole | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | 11 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 12 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $124.72 · 4 records | GlaxoSmithKline, LLC. | NURTEC ODT, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PBG PUERTO RICO LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error